A groundbreaking discovery in pancreatic cancer treatment reveals that the epigenetic silencing of the BEND4 gene can enhance the effectiveness of ATM inhibitors. The study shows that BEND4 is frequently methylated and silenced in pancreatic cancer, affecting DNA damage repair. Through cell line experiments and tissue analysis, researchers found that BEND4 methylation is associated with poor tumor differentiation and prognosis in pancreatic cancer patients. Additionally, the study demonstrated that loss of BEND4 expression combined with ATM inhibitor treatment has a synthetic lethal effect, making BEND4 methylation a potential biomarker for predicting response to ATM inhibitors in pancreatic cancer therapy. This research opens new possibilities for targeted therapies in pancreatic cancer treatment.
Source link
Epigenetic silencing of BEND4 unveils new path for PDAC treatment
